[Click eStock] "DIO, Notable 30% Annual Growth... Target Price Up 20%"

[Asia Economy Reporter Jihwan Park] Yuanta Securities maintained a 'Buy' rating on DIO on the 20th, citing its outstanding annual performance growth rate of over 30%, and raised the target price by 20% from 60,000 KRW to 72,000 KRW.

Researcher Juwon An of Yuanta Securities stated, "DIO is introducing various products that go beyond simple implant sales based on full digital solutions, enabling both expansion in scale and increased profitability," adding, "With an annual growth rate exceeding 30%, its performance is expected to continue expanding, making it highly attractive for investment."

DIO signed a digital implant supply contract worth approximately 50 billion KRW over three years with China's largest online dental material distribution platform company the day before. Alongside this, news was also announced that Straumann, the global No.1 implant company, is considering acquiring shares in DIO.

Researcher An evaluated, "Firstly, the supply contract with China shows that DIO is benefiting from the high growth of the global dental market centered in China, reaffirming the competitiveness of its products," and added, "With Straumann's consideration of share acquisition revealing a major outline related to the sale, uncertainties are also being resolved." Both events are positive, so DIO's stock price is expected to continue rising.

DIO's domestic sales this year are projected to reach 49.6 billion KRW, a 38.6% increase compared to the previous year. Achieving domestic sales in the 40 billion KRW range for the first time in four years since 2017 is attributed to the significant contribution of the edentulous solution. The edentulous solution is a product developed for patients who have used dentures for a long time or have left tooth loss untreated without additional treatment, and it is highly regarded for its precision. In May, DIO also signed an annual supply contract worth about 8 billion KRW for the edentulous solution with a Chinese medical device distributor, making overseas achievements visible.

Significant sales growth in the United States is also expected next year. Researcher An emphasized, "Through cooperation with a large dental network in the U.S., DIO is expected to have the strongest sales power among domestic dental companies," and added, "We can fully anticipate positive results in the U.S. market as well."

This content was produced with the assistance of AI translation services.